In This Section

Program: Friday, February 20

Wednesday, Feb. 18 Thursday, Feb. 19 Saturday, Feb. 21

FRIDAY, FEBRUARY 20

* – Short talk selected from proffered abstracts
[R] – Remote presentation

Friday, February 20

Breakfast

7-8 a.m. | Diamond Ballroom 1-3

Keynote Session 3

8-9:20 a.m. | Diamond Ballroom 5-10

  • 8 a.m. | Introduction of Keynote Speaker
  • 8:05 a.m. | Keynote
    LAG-3: The third checkpoint inhibitor and its synergistic interactions with PD1
    Dario A. Vignali, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • 8:40 a.m. | Introduction of Keynote Speaker
  • 8:45 a.m. | Keynote
    Immunology of poorly-immunogenic tumor
    Lieping Chen, Yale University, New Haven, Connecticut

Break

9:20-9:30 a.m. | Diamond Ballroom Foyer

Major Symposia 5-6

9:30-11 a.m.

Major Symposium 5: New Breakthroughs in TCR Engineering

Diamond Ballroom 5-10

Session Chair: Owen N. Witte, University of California, Los Angeles, California

  • 9:35 a.m. | Cancer immunotherapy: Target, modality, and timing
    Owen N. Witte
  • 9:55 a.m. | Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, New York, New York
  • 10:15 a.m. | Programmable JAK/STAT signaling drives CAR T cells to enhanced functional states*
    Wansang Cho, Stanford University, Stanford, California
  • 10:25 a.m. | Developing TCR-based precision immunotherapies for EGFR-mutant NSCLC*
    Yongfeng He, Weill Cornell Medicine, New York, New York
  • 10:35 a.m. | Discussion / Q&A

Major Symposium 6: TILs and Maintenance of Immunity

Diamond Ballroom 4

Session Chair: Brian Gastman, Iovance Biotherapeutics, San Carlos, California

  • 9:35 a.m. | TILs – The next generation: Genetically modified TIL expressing regulatable membrane-bound IL15
    Parameswaran Hari, Obsidian Therapeutics, Cambridge, Massachusetts
  • 9:55 a.m. | Brian Gastman
  • 10:15 a.m. | p53 promotes anti-tumor immunity of human CD8+ T cells*
    Joseph G. Crompton, University of California, Los Angeles, California
  • 10:25 a.m. | Reprogramming the tumor microenvironment enables T cell-mediated immunotherapies in pediatric solid cancers*
    Simon Krost, Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
  • 10:35 a.m. | Discussion / Q&A

Break

11-11:15 a.m. | Diamond Ballroom Foyer

Spotlight on Proffered Papers Session 4

11:15 a.m.-12 p.m. | Diamond Ballroom 5-10

Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 11:19 a.m. | Postprandial changes to systemic lipid metabolism enhances adaptive immunity*
    Alok Kumar, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 11:26 a.m. | Histone methyltransferase PRMT5 promotes melanoma immune evasion by repressing T H 1-related gene networks and endogenous retroelements*
    Simon Milette, Yale University, New Haven, Connecticut
  • 11:33 a.m. | TET1 orchestrates glucose metabolism and counteracts TNBC aggressiveness under the oncogenic stress*
    Hsin-Ling Hsu, National Health Research Institutes, Zhunan, Taiwan
  • 11:40 a.m. | The T cell precursor frequency determines the immunogenicity of cancer neoantigens*
    Tzu-Jiun Kuo, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
  • 11:47 a.m. | Leveraging PSGL-1 blockade to elicit responses to anti-PD-1 immunotherapy resistant melanoma*
    Hannah A.F. Hetrick, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California
  • 11:54 a.m. | Targeting cancer-intrinsic neddylation overcomes resistance to immune checkpoint blockade therapy in interferon-deficient tumors*
    Marta Rúbies Bedós, Uppsala University, Uppsala, Sweden

Poster Session C / Exhibit Show / Lunch

12:15-3:15 p.m. | Platinum Ballroom

Major Symposia 7-8

3:15-4:45 p.m.

Major Symposium 7: In vivo T Cell Engineering – Are We There Yet?

Diamond Ballroom 5-10

Session Chair: Justin Eyquem, Gladstone-UCSF Institute of Genomic Immunology, San Francisco, California

  • 3:20 p.m. | Haig Aghajanian, Capstan Therapeutics, San Diego, California [R]
  • 3:40 p.m. | Kevin Friedman, Kelonia Therapeutics, Boston, Massachusetts
  • 4 p.m. | Justin Eyquem
  • 4:20 p.m. | Discussion / Q&A

Major Symposium 8: Neuro-Psych-Immunology in IO and Late-Breaking Clinical Trials Session

Diamond Ballroom 4

Session Chair: John B.A.G. Haanen, Netherlands Cancer Institute, Amsterdam, Netherlands

  • 3:20 p.m. | From brain to cancer: Harnessing serotonin and antidepressants for immunotherapy
    Lili Yang
  • 3:40 p.m. | Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: The phase II NIBIT-ML1 study*
    Anna Maria Di Giacomo, University of Siena and Center for Immuno-Oncology, Siena, Italy
  • 3:50 p.m. | Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing Phase I trial*
    Tim Remus, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut
  • 4 p.m. | Phase 1 trial of bispecific CART19/20 cells for relapsed or refractory Non-Hodgkin Lymphoma: Updated results with over two years median follow up*
    Sophie Carlson, University of California, Los Angeles, California
  • 4:10 p.m. | No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404*
    Megan Othus, Fred Hutchinson Cancer Center, Seattle, Washington
  • 4:20 p.m. | Discussion / Q&A

Break

4:45-5 p.m. | Diamond Ballroom Foyer

Spotlight Sessions 3-4

5-6:20 p.m.

Spotlight Session 3: Novel T-cell Engagers

Diamond Ballroom 5-10

Session Chair: Paresh Vyas, University of Oxford, Oxford, United Kingdom

  • 5:05 p.m. | Paresh Vyas
  • 5:25 p.m. | Patrick A. Baeuerle, Cullinan Therapeutics, Cambridge, Massachusetts
  • 5:45 p.m. | Agonistic CD137 (4-1BB) anchored immunotherapy (ANK-203) elicits potent 4-1BBL signaling in vitro and therapeutic responses against established tumors without systemic toxicity in vivo*
    Robert G. Newman, Ankyra Therapeutics, Cambridge, Massachusetts
  • 5:55 p.m. | Antibody-lectin chimeras for glyco-immune checkpoint blockade*
    Megan J. Priestley, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • 6:05 p.m. | Discussion / Q&A

Spotlight Session 4: Systems Immunology

Diamond Ballroom 4

Session Chair: Garry P. Nolan, Stanford University School of Medicine, Stanford, California

  • 5:05 p.m. | Garry P. Nolan
  • 5:25 p.m. | A multiscale view of tumor ecosystems: From single-cell states to functional immune niches and communities
    Linghua Wang, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:45 p.m. | Discussion / Q&A

Evening off / Dinner on own

6:20 p.m.